Osaic Holdings
ZNTL icon

Osaic Holdings’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Osaic Holdings’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$12 – 8020
2025
Q2 		$12 Hold
10
– – ﹤0.01% 7680
2025
Q1 		$16 Sell
10
-172
-95% -$371 ﹤0.01% 7362
2024
Q4 		$551 Sell
182
-15
-8% -$49 ﹤0.01% 6997
2024
Q3 		$724 Sell
197
-58
-23% -$211 ﹤0.01% 6927
2024
Q2 		$1.04K Sell
255
-76
-23% -$849 ﹤0.01% 6806
2024
Q1 		$5.21K Sell
331
-320
-49% -$4.4K ﹤0.01% 6066
2023
Q4 		$9.86K Sell
651
-643
-50% -$9.38K ﹤0.01% 5836
2023
Q3 		$26K Buy
1,294
+647
+100% +$16.4K ﹤0.01% 5410
2023
Q2 		$18.2K Buy
+647
New +$15.5K ﹤0.01% 5628
2022
Q3 		– Sell
-962
Closed -$27K – 7547
2022
Q2 		$27K Sell
962
-150
-13% -$3.97K ﹤0.01% 5412
2022
Q1 		$51K Sell
1,112
-106
-9% -$5.72K ﹤0.01% 5086
2021
Q4 		$102K Buy
1,218
+1,115
+1,083% +$86.3K ﹤0.01% 4586
2021
Q3 		$7K Buy
+103
New +$5.94K ﹤0.01% 6408
2021
Q1 		– Sell
-7
Closed – – 6968
2020
Q4 		$0 Sell
7
-1,298
-99% -$58.5K ﹤0.01% 6604
2020
Q3 		$43K Buy
1,305
+305
+31% +$10.7K ﹤0.01% 4421
2020
Q2 		$48K Buy
+1,000
New +$38.4K ﹤0.01% 4221

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings's ZNTL Position: Q3 2025 in Review

Osaic Holdings sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 10 shares — an estimated $12 sold.

Osaic Holdings first reported a position in ZNTL in Q2 2020 and held it in 16 quarters. The position peaked at $102K in Q4 2021. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

  • Osaic Holdings reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Osaic Holdings sold 10 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $12.
  • Osaic Holdings first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 16 quarters.
  • Osaic Holdings's Zentalis Pharmaceuticals position peaked at $102K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Osaic Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.